Loading...
Loading...
IRWD| Name | Value |
|---|---|
| Revenues | 117.6M |
| Cost of Revenue | 0.5M |
| Gross Profit | 117.0M |
| Operating Expense | 72.6M |
| Operating I/L | 44.4M |
| Other Income/Expense | -7.2M |
| Interest Income | 1.2M |
| Pretax | 30.4M |
| Income Tax Expense | 32.1M |
| Net Income/Loss | -1.1M |
Ironwood Pharmaceuticals, Inc. is a healthcare company specializing in the development and commercialization of gastrointestinal (GI) products. Its flagship product, LINZESS, is a treatment for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company also markets CONSTELLA in Canada and the European Union. Ironwood Pharmaceuticals is actively developing IW-3300, a GC-C agonist for visceral pain conditions, and CNP-104, an immune nanoparticle for biliary cholangitis treatment. The company generates revenue through the sales of its GI products and has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for product development and commercialization.
